The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
Neurogenic bladder for at least 6 months;
Utilizing indwelling catheterization for bladder management;
Women must be premenopausal and not currently menstruating;
Community dwelling
Use of prophylactic antibiotics;
Instillation of intravesical antimicrobials to prevent UTI;
Psychologic or psychiatric conditions influencing the ability to follow instructions;
Use of oral or IV antibiotics within the past 2 weeks;
Medstar Health Research Institute
Lead sponsor
Children's National Research Institute
Collaborator